CNB Bank’s Intellia Therapeutics NTLA Stock Holding History

CNB Bank’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-200	Closed	-$3K	–	462
2019 Q2	$3K	Hold	200	–	–	﹤0.01%	441
2019 Q1	$3K	Hold	200	–	–	﹤0.01%	350
2018 Q4	$3K	Hold	200	–	–	﹤0.01%	314
2018 Q3	$6K	Hold	200	–	–	﹤0.01%	265
2018 Q2	$5K	Hold	200	–	–	﹤0.01%	266
2018 Q1	$4K	Hold	200	–	–	﹤0.01%	268
2017 Q4	$4K	Buy	+200	New	+$4.62K	﹤0.01%	307

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CNB Bank's NTLA Position: Q3 2019 in Review

CNB Bank sold out of Intellia Therapeutics (NTLA) in Q3 2019, closing a stake of 200 shares — an estimated $3K sold.

CNB Bank first reported a position in NTLA in Q4 2017 and held it in 7 quarters. The position peaked at $6K in Q3 2018. 136 funds tracked by Wall St. Rank hold NTLA as of Q3 2019.

CNB Bank reported no remaining Intellia Therapeutics position as of Q3 2019 after selling out during the quarter.
CNB Bank sold 200 Intellia Therapeutics shares in Q3 2019, an estimated $3K.
CNB Bank first reported a position in Intellia Therapeutics in Q4 2017 and held it in 7 quarters.
CNB Bank's Intellia Therapeutics position peaked at $6K in Q3 2018.
136 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2019.

Based on CNB Bank's 13F filing for Q3 2019, filed 4 Nov 2019.